OTLK

$0.66+2.69%website ↗

Outlook Therapeutics, Inc.

Market Cap

$162M

Sector

Materials

Industry

Biological Products, (No Diagnostic Substances)

Beta

0.63

5yr monthly vs SPY

Price Chart

Loading…

Signals

Insider Velocity

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

10 analysts

Velocity Score

29.44x

Current Rate (90d)

133367.31/mo

Baseline Rate

0.00/mo

Unique Buyers (90d)

9

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-14	2026-08-14	KENYON LAWRENCE A	Director & Chief Financial Officer	Purchase	101.0K	—	—	107.0K	View
2026-08-14	2026-08-14	Jahr Robert Charles	Director & Chief Executive Officer	Purchase	151.5K	—	—	151.5K	View
2026-08-12	2026-08-14	Sukhtian Ghiath M.	Director	Purchase	2.53M	$0.99	$2.50M	24.62M	View
2026-07-29	2026-07-29	Sukhtian Faisal Ghiath	Director	Purchase	95.4K	$1.05	$100K	221.0K	View
2026-06-02	2026-06-03	Haddadin Yezan Munther	Director	Purchase	29.0K	$0.83	$24K	66.2K	View

1–5 of 10

1 / 2

Recent News

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Yahoo · 2026-08-27

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Yahoo · 2026-08-27

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Yahoo · 2026-08-17

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

Benzinga · 2026-08-17

Informational purposes only, not investment advice.